@pennakiz.bsky.social
Reposted
www.youtube.com/watch?v=QnFb...
RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.
Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)
RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.
Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)
CROI 2025 Monday (March 10) Press Conference
YouTube video by IAS-USA
www.youtube.com
March 11, 2025 at 7:24 PM
www.youtube.com/watch?v=QnFb...
RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.
Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)
RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.
Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)
Reposted
Prof Sarah Fidler presents the long-awaited results of #RIOstudy of dual bNAbs vs placebo in people with early HIV.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
March 10, 2025 at 6:48 PM
Prof Sarah Fidler presents the long-awaited results of #RIOstudy of dual bNAbs vs placebo in people with early HIV.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.